

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CLINUVEL PHARMACEUTICALS LTD</b>
<b>ABN</b>	<b>88 089 644 119</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Philippe Wolgen
<b>Date of last notice</b>	05 August 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect Interest (Ordinary Shares)  Direct Interest (Unlisted Conditional Performance Rights)
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder: ACN 108 768 896 PTY LTD)
<b>Date of change</b>	11 March 2019
<b>No. of securities held prior to change</b>	2,579,722 Ordinary Shares (includes 2,474,836 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust)  924,974 Unlisted Conditional Performance Rights
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	716,642 Ordinary Shares
<b>Number disposed</b>	716,642 Unlisted Conditional Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil

<b>No. of securities held after change</b>	3,296,364 Ordinary Shares (includes 3,191,478 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust)  208,332 Unlisted Conditional Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan(s) upon achievement of a performance condition, the issue of Rights to the Director as approved by shareholders at the Company's 2010 and 2014 Annual General Meetings.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CLINUVEL PHARMACEUTICALS LTD</b>
<b>ABN</b>	<b>88 089 644 119</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Stan McLiesh
<b>Date of last notice</b>	23 December 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect Interest (Ordinary Shares)  Direct Interest (Unlisted Conditional Performance Rights)
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder: ACN 108 768 896 PTY LTD)
<b>Date of change</b>	11 March 2019
<b>No. of securities held prior to change</b>	162,774 Ordinary Shares (includes 135,000 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust)  65,000 Unlisted Conditional Performance Rights
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	25,000 Ordinary Shares
<b>Number disposed</b>	25,000 Unlisted Conditional Performance Rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil

<b>No. of securities held after change</b>	187,774 Ordinary Shares (includes 160,000 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust)  40,000 Unlisted Conditional Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan upon achievement of a performance condition, the issue of Rights to the Director as approved by shareholders at the Company's 2014 Annual General Meeting.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CLINUVEL PHARMACEUTICALS LTD</b>
<b>ABN</b>	<b>88 089 644 119</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brenda Shanahan
<b>Date of last notice</b>	29 January 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect Interest (Ordinary Shares)  Direct Interest (Unlisted Conditional Performance Rights)
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> <li>San Luis Nominees Pty Ltd (trustee for the Brenda Shanahan Superannuation Fund)</li> <li>Ordinary shares held on behalf of Director by the Clinuvel Conditional Performance Rights Scheme Trust (Registered Holder: ACN 108 768 896 PTY LTD)</li> <li>Brenda Shanahan Charitable Foundation of which the director is a Trustee to the foundation</li> </ol>
<b>Date of change</b>	11 March 2019
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>53,969 Ordinary Shares (San Luis Nominees Pty Ltd)</li> <li>100,000 Ordinary shares (Clinuvel Conditional Performance Rights Scheme Trust )</li> <li>80,000 Ordinary shares (Brenda Shanahan Charitable Foundation of which the director is a Trustee to the foundation)</li> </ol> 50,000 Unlisted Conditional Performance Rights
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	25,000 Ordinary Shares
<b>Number disposed</b>	25,000 Unlisted Conditional Performance Rights

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$Nil
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 53,969 Ordinary Shares (San Luis Nominees Pty Ltd)</li> <li>2. 125,000 Ordinary shares (Clinuvel Conditional Performance Rights Scheme Trust )</li> <li>3. 80,000 Ordinary shares (Brenda Shanahan Charitable Foundation of which the director is a Trustee to the foundation)</li> </ol> <p>25,000 Unlisted Conditional Performance Rights</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Conditional Performance Rights ('Rights') under the company's Performance Rights Plan upon achievement of a performance condition, the issue of Rights to the Director as approved by shareholders at the Company's 2014 Annual General Meeting.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a